静脉注射 Palifosfamide-tris 联合依托泊苷和卡铂治疗恶性肿瘤患者
静脉注射 (IV) Palifosfamide-tris 联合静脉注射依托泊苷和静脉注射卡铂治疗恶性肿瘤患者的 I 期研究,其中依托泊苷和卡铂是合适的选择
This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Indiana University Simon Cancer Center
-
Lafayette、Indiana、美国、47905
- Horizon Oncology Research
-
Muncie、Indiana、美国、47303
- Medical Consultants, PC
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 years old or greater
- Malignancy scheduled to receive etoposide and carboplatin therapy
- Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1
- Adequate bone marrow, liver, renal function and coagulation status
- Informed consent
- Agree to use birth control through 28 days of last treatment dose
- Pregnancy test for women of child-bearing potential
- No available standard therapy
Exclusion Criteria:
- Allergy to the the study treatment drugs
- Unstable current medical condition
- Presence or history of injury to the urinary tract
- Active infection
- Major surgery within 4 weeks prior to treatment
- Minor surgery within 2 weeks prior to treatment
- Current acute steroid therapy or taper
- Currently pregnant or nursing
- Substance abuse or condition that may interfere with participation
- Received other investigational drugs within 30 days
- Within 4 weeks of their last chemotherapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:PaCE
Palifosfamide, Carboplatin and Etoposide |
Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assess the safety profile
大体时间:21 Days
|
Adverse events, vital signs, physical examination, laboratory data and concomitant medications |
21 Days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Determine the maximum tolerated dose
大体时间:Up to 21 days
|
Each dose level cohort will be 3 subjects. After 3 subjects have received a regimen, there will be a minimum observation period of 1 full cycle (21 days) for each of the 3 subjects before enrollment of the group of subjects at the next dose level. |
Up to 21 days
|
|
Assess early signs of efficacy
大体时间:duration of study
|
To assess early signs of efficacy using this investigational combination in this patient population |
duration of study
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IPM1004
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.